0000950170-24-040358.txt : 20240402 0000950170-24-040358.hdr.sgml : 20240402 20240402171433 ACCESSION NUMBER: 0000950170-24-040358 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240401 FILED AS OF DATE: 20240402 DATE AS OF CHANGE: 20240402 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lees-Rolfe Garth CENTRAL INDEX KEY: 0002017374 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39676 FILM NUMBER: 24815535 MAIL ADDRESS: STREET 1: 1 CRANBERRY HILL STREET 2: SUITE 200 CITY: LEXINGTON STATE: MA ZIP: 02421 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Inhibikase Therapeutics, Inc. CENTRAL INDEX KEY: 0001750149 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 263407249 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3350 RIVERWOOD PARKWAY SE, SUITE 1900 CITY: ATLANTA STATE: GA ZIP: 30339 BUSINESS PHONE: 678-392-3419 MAIL ADDRESS: STREET 1: 3350 RIVERWOOD PARKWAY SE, SUITE 1900 CITY: ATLANTA STATE: GA ZIP: 30339 4 1 ownership.xml 4 X0508 4 2024-04-01 0001750149 Inhibikase Therapeutics, Inc. IKT 0002017374 Lees-Rolfe Garth 1 CRANBERRY HILL, SUITE 200 LEXINGTON MA 02421 false true false false Chief Financial Officer false Stock Option (right to buy) 2.16 2024-04-01 4 A false 90000 0.00 A 2031-04-01 Common Stock 90000 90000 D One-third of the options will vest and become exercisable on April 1, 2025, one-third of the options will vest and become exercisable on April 1, 2026, and one-third of the options will vest and become exercisable on April 1, 2027, in each case subject to continued employment through each such vesting date. /s/ Garth Lees-Rolfe 2024-04-02